Curis (CRIS) Stock Forecast & Price Target

Curis is supported by strengthening PCNSL data for emavusertib plus ibrutinib, including a 100% ORR in five of five BTKi-naïve evaluable patients and 33% ORR in 30 BTKi-experienced evaluable patients, which improves the registrational case and supports potential accelerated approval in the U.S. and Conditional Marketing Authorization in Europe. The company also has a compelling mechanistic rationale in CLL, where BTKi monotherapy yields high but shallow responses, while dual blockade of BCR and TLR signaling has already shown deeper responses, including CRs and undetectable MRD, when emavusertib is added to a BTKi regimen. Execution is improving as well, with 11 sites opened on June 26, 10 patients consented as of July 22, and guidance moving to 5-10 patients in December 2026, suggesting growing clinical interest and advancing pipeline momentum.

Curis is a highly speculative biotechnology name whose valuation depends heavily on emavusertib, with 56% of modeled value tied to PCNSL, 24% to AML/MDS, and 20% to CLL, leaving the equity exposed to any delay or disappointment in a narrow set of clinical catalysts. The key bearish issue is financing risk: management’s own outlook implies PCNSL full enrollment by 2027, a 2029 launch, and AML/MDS pushed to 2032 because further development is contingent on additional funding, signaling a stretched capital path. With failed or inconclusive trials, undisclosed durability and safety data, and only a 10% probability of success assigned to CLL, the downside risk from clinical and dilution uncertainty remains elevated.